These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11524661)

  • 1. Two cases of withdrawal from 1,4-Butanediol use.
    Mycyk MB; Wilemon C; Aks SE
    Ann Emerg Med; 2001 Sep; 38(3):345-6. PubMed ID: 11524661
    [No Abstract]   [Full Text] [Related]  

  • 2. Consequences of 1,4-Butanediol Misuse: A Review.
    Skryabin V; Shevtsova Y; Novoselova EA
    Psychopharmacol Bull; 2023 Dec; 53(4):48-53. PubMed ID: 38076667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review.
    Wojtowicz JM; Yarema MC; Wax PM
    CJEM; 2008 Jan; 10(1):69-74. PubMed ID: 18226321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events, including death, associated with the use of 1,4-butanediol.
    Zvosec DL; Smith SW; McCutcheon JR; Spillane J; Hall BJ; Peacock EA
    N Engl J Med; 2001 Jan; 344(2):87-94. PubMed ID: 11150358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comment on "The abrupt cessation of therapeutically administered sodium oxybate (GHB) may cause withdrawal symptoms".
    Zvosec DL; Smith SW
    J Toxicol Clin Toxicol; 2004; 42(1):121-3; author reply 125-7. PubMed ID: 15083950
    [No Abstract]   [Full Text] [Related]  

  • 6. [Withdrawal syndrome after abuse of GHB (Gamma-Hydroxybutyrate) and its physiological precursors - its relevance for child and adolescent psychiatrists].
    Zepf FD; Holtmann M; Duketis E; Maier J; Radeloff D; Schirman S; Wagner A; Poustka F; Wöckel L
    Z Kinder Jugendpsychiatr Psychother; 2009 Sep; 37(5):413-20. PubMed ID: 19739059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. gamma-Hydroxybutyrate withdrawal and chloral hydrate.
    Hutto B; Fairchild A; Bright R
    Am J Psychiatry; 2000 Oct; 157(10):1706. PubMed ID: 11007738
    [No Abstract]   [Full Text] [Related]  

  • 8. Gamma-hydroxy butyrate withdrawal delirium: a case report.
    Miglani JS; Kim KY; Chahil R
    Gen Hosp Psychiatry; 2000; 22(3):213-5. PubMed ID: 11012302
    [No Abstract]   [Full Text] [Related]  

  • 9. Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal.
    Perez E; Chu J; Bania T
    Ann Emerg Med; 2006 Aug; 48(2):219-20. PubMed ID: 16857475
    [No Abstract]   [Full Text] [Related]  

  • 10. Gamma hydroxybutyrate withdrawal in an orthopedic trauma patient.
    Slagel B; Kingstone E; Bhalerao S
    Can J Psychiatry; 2003 Mar; 48(2):131-2. PubMed ID: 12655920
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute toxicity and withdrawal syndromes related to γ-hydroxybutyrate (GHB) and its analogues γ-butyrolactone (GBL) and 1,4-butanediol (1,4-BD).
    Wood DM; Brailsford AD; Dargan PI
    Drug Test Anal; 2011; 3(7-8):417-25. PubMed ID: 21548140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [GHB--dangerous, addictive and uncontrollable "party drug"].
    Persson SA; Eriksson A; Hallgren N; Eklund A; Berkowicz A; Druid H
    Lakartidningen; 2001 Sep; 98(38):4026-31, 4033-5. PubMed ID: 11602959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The behavioural profile of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol in humans.
    Bosch OG; Seifritz E
    Brain Res Bull; 2016 Sep; 126(Pt 1):47-60. PubMed ID: 26855327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epileptic seizure in GHB withdrawal.
    Chew G; Fernando A
    Australas Psychiatry; 2004 Dec; 12(4):410-1. PubMed ID: 15715821
    [No Abstract]   [Full Text] [Related]  

  • 15. New recreational drugs and the primary care approach to patients who use them.
    Winstock AR; Mitcheson L
    BMJ; 2012 Feb; 344():e288. PubMed ID: 22337751
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of severe withdrawal from gamma-hydroxybutyrate.
    Chin RL
    Ann Emerg Med; 2001 May; 37(5):551-2. PubMed ID: 11326198
    [No Abstract]   [Full Text] [Related]  

  • 17. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use.
    Corkery JM; Loi B; Claridge H; Goodair C; Corazza O; Elliott S; Schifano F
    Neurosci Biobehav Rev; 2015 Jun; 53():52-78. PubMed ID: 25843781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-patient detoxification after GHB dependence.
    Price G
    Br J Psychiatry; 2000 Aug; 177():181. PubMed ID: 11026962
    [No Abstract]   [Full Text] [Related]  

  • 19. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
    Schep LJ; Knudsen K; Slaughter RJ; Vale JA; Mégarbane B
    Clin Toxicol (Phila); 2012 Jul; 50(6):458-70. PubMed ID: 22746383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Within-patient variability in clinical presentation of gamma-hydroxybutyrate withdrawal: a case report.
    Glasper A; McDonough M; Bearn J
    Eur Addict Res; 2005; 11(3):152-4. PubMed ID: 15990433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.